Emerging biotech sponsors should adopt AI in clinical operations in a deliberate sequence: first govern what vendors already use, then add low-risk productivity tools, then invest in targeted analytics tied to specific program risks. Trying to do everything at once usually produces expensive software and little change.
Small sponsors face a particular version of the AI question. They lack large internal teams, so they rely heavily on CROs and vendors. They are under pressure from investors to move fast and spend carefully. And they are pitched constantly by technology companies promising transformation.
Where should a small biotech start with AI?
I suggest a four-stage sequence.
Stage 1: Understand what you already have. Your CRO, EDC provider, eTMF vendor and safety vendor are likely using AI on your behalf. Before buying anything, ask them what they use, how it is validated and what data it touches. This costs nothing and closes an oversight gap.
Stage 2: Improve internal productivity safely. Approved generative AI tools can help lean teams draft documents, summarize vendor reports, prepare governance meeting materials and review contracts. Set a clear acceptable use policy first. The return is immediate and the risk is manageable.
Stage 3: Target your biggest operational risk. Identify the single problem most likely to delay your next milestone. For many emerging sponsors it is enrollment. For others it is vendor performance visibility or protocol feasibility. Choose an AI capability that addresses that specific problem, and measure it.
Stage 4: Build data assets over time. As you run more studies, structure and retain your operational data: site performance, vendor KPIs, cycle times. That history becomes the foundation for better decisions and more useful analytics later.
What small sponsors should avoid
Avoid buying enterprise platforms designed for global pharma. Avoid tools that require data you do not have. Avoid adopting AI to compensate for missing processes, because it will expose those gaps rather than fill them. And avoid letting a CRO's technology stack become the main reason you select that CRO, unless it directly addresses your study's risk.
The investor conversation
Boards and investors increasingly ask how a company is using AI. A thoughtful, sequenced answer is far more credible than a list of tools. "We govern what our vendors use, we have improved team productivity with controlled tools, and we are applying predictive enrollment analytics to our pivotal study" is a strong answer. It shows discipline.
Leverage experience, not just technology
For lean organizations, the right experienced leader is often a bigger accelerator than any tool. Someone who has seen how studies fail can point AI at the problems that matter. That is where fractional leadership and targeted technology work well together.
Not sure where your operations stand? ABRA's Clinical Trial Readiness Check is a free starting point.
